Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The company has three technologies - PI3K inhibitors, superbenzopyran, and anti-tropomyosin. The group is developing GDC-0084, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; Trilexium, has a potential application across a range of different cancer types.
| Website: | www.novogen.com |
| Email: | investment.consultant@novogen.com |
| Main Phone: | +61 294724101 |
| Address: | 300 Barangaroo Avenue |
| Address 2: | Level 24 |
| State: | NSW |
| City / Town: | Sydney |
| Country: | AUS |
| Postal Code: | 2000 |
| Exchange: | GREY |
| CEO: | James Garner |
| Employees: | 5 |
Gathering Data... Please wait Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The company has three technologies - PI3K inhibitors, superbenzopyran, and anti-tropomyosin. The group is developing GDC-0084, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; Trilexium, has a potential application across a range of different cancer types.
| Website: | www.novogen.com |
| Email: | investment.consultant@novogen.com |
| Main Phone: | +61 294724101 |
| Address: | 300 Barangaroo Avenue |
| Address 2: | Level 24 |
| State: | NSW |
| City / Town: | Sydney |
| Country: | AUS |
| Postal Code: | 2000 |
| Exchange: | GREY |
| CEO: | James Garner |
| Employees: | 5 |
| Last Price 0.0351 | Change $ 0. | Change % 0.00 | Tick N/A |
| Bid N/A | Bid Size 0.00 | Ask N/A | Ask Size 0.00 |
| Open N/A | High N/A | Low N/A | Prev Close 0.0351 |
| Last Trade | Volume 0 | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap 2.2 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 62,166,673.00 | EPS (TTM) -0.09 | PE Ratio N/A | Exchange Greys |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
